Genentech, Inc. (NYSE:DNA) today announced the appointment of Jennifer A. Doudna, Ph.D., to Vice President, Discovery Research. In this newly created position, Doudna will oversee the departments of protein chemistry and structural biology. She will be a member of the small molecule drug discovery senior leadership team and will participate in therapeutic RNA discovery efforts. Doudna will report to Richard Scheller, Executive Vice President, Research and Chief Scientific Officer.
“Jennifer is recognized internationally as one of the foremost experts in the structure and biological functions of ribonucleic acids (RNAs) and was a pioneer in developing a molecular understanding of catalytic RNAs,” said Scheller. “We are delighted to have Jennifer join the R&D leadership team. Her interests and expertise make her a vital addition to our ongoing drug discovery efforts.”
Doudna joins Genentech from the University of California, Berkeley, where she has been a Professor in the Department of Molecular and Cell Biology and the Department of Chemistry as well as a Howard Hughes Medical Institute Investigator. Prior to coming to Berkeley, Doudna was Henry Ford II Professor in the Department of Molecular Biophysics and Biochemistry at Yale University. Among many honors, Doudna is a Member of the National Academy of Sciences and the American Academy of Arts and Sciences.
Doudna is a member of numerous scientific advisory boards, serves on the editorial boards of several scientific journals, and has published more than 100 scientific papers and review articles.
Doudna received a bachelor of arts in chemistry from Pomona College in Claremont, California, and her Ph.D. in biochemistry from Harvard University. She did postdoctoral work in molecular biology at Massachusetts General Hospital, in genetics at the Harvard Medical School, and in biomedical science in the Department of Chemistry and Biochemistry at the University of Colorado before joining the faculty at Yale.
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with significant unmet medical needs. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.